Home Compare AMGN vs LLY
Stock Comparison · Industry comparison · Drug Manufacturers - General

Amgen vs Eli Lilly and Company: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Eli Lilly and Company carrying a narrow edge on profitability. Amgen still leads on valuation and stability, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Most of the separation is still concentrated in profitability.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. AMGN and LLY share the same industry classification.

For a similarity-based comparison, see how Amgen and Eli Lilly and Company each position within their functional peer groups in AssetNext.

Peer-Relative Score
AMGN
Amgen Inc.
63
Peer-Score
Signal qualityHigh
vs
LLY
Eli Lilly and Company
68
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in profitability.

Dimension spread: AMGN vs LLY Profitability 50 100 Stability 57 34 Valuation 73 44 Growth 75 88 AMGN LLY
Gap Ranking
#1 Profitability +50
#2 Valuation +29
#3 Stability +23
#4 Growth +13
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for AMGN and LLY Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer AMGNLLY Relative valuation Structural strength

Eli Lilly and Company occupies the cheaper side of the setup map, although Amgen Inc. still holds the stronger structural profile.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
Both rank well on profitability, but Eli Lilly and Company still holds a clear edge.
Valuation
On valuation, the same pattern holds: both are strong, but Amgen Inc. still leads clearly.
Profitability — Dominant Gap
AMGN
50
LLY
100
Gap+50in favour of LLY

The profitability lead is mainly driven by a 14.3-point operating margin advantage.

What keeps the gap from being one-sided

Absolute pricing still looks more supportive for Amgen, with a forward P/E that is 6.9 turns lower there.

What this means for the comparison

Profitability points more clearly to Eli Lilly and Company, but valuation and current pricing keep the broader result mixed.

Explore full peer positioning in AssetNext

Break down the AMGN vs LLY comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how AMGN and LLY each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.